Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial
Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback, prompting the French drugmaker to pull back from monotherapy plans.
Nick Paul Taylor
Apr 24, 2025 4:46am
Mural's IL-2 flop triggers 90% staff reduction
Apr 15, 2025 9:33am
Sanofi's hopes for $1.1B Kymab drug dented after ph. 2 asthma fail
Apr 15, 2025 7:34am
Alzheon Alzheimer's drug knocked down in pivotal APOLLOE4 bout
Apr 10, 2025 8:48am
Rallybio drops lead program as phase 2 data disappoint
Apr 8, 2025 8:52am
BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects
Apr 3, 2025 8:05am
